PDPN and neoplasm: PDPN (podoplanin), a transmembrane glycoprotein broadly expressed by CAFs across tumor types, has been effectively targeted in preclinical models using monoclonal antibodies and CAR-T approaches, resulting in robust anti-tumor activity [34].